Search - tctmd.com

Displaying 1 - 20 of 62

Sort: Relevancy | Date

Top News in Heart Rhythm: 2018

News Features

Top News in Heart Rhythm: 2018

December 28, 2018

Top News in Coronary Artery Disease: 2018

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

Top News in Structural Heart Disease: 2018

News Features

Top News in Structural Heart Disease: 2018

December 28, 2018

Barbershop Intervention for High BP Has Lasting Effects

News Daily News

Barbershop Intervention for High BP Has Lasting Effects

December 19, 2018

Is It Time to Loosen Restrictions on Saturated Fats and Salt?

News Conference News WCC 2018

Is It Time to Loosen Restrictions on Saturated Fats and Salt?

December 14, 2018

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

News Daily News

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

December 11, 2018

NOACs Significantly Curb Risk of VTE in Cancer Patients

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

December 06, 2018

Current or Prior Cancers Affect PCI Outcomes Differently, Large Analysis Shows

News Daily News

Current or Prior Cancers Affect PCI Outcomes Differently, Large Analysis Shows

December 04, 2018

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

News Daily News

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

Michael O'Riordan

November 23, 2018

Concerning Decline in Antibiotic Prophylaxis for Infective Endocarditis

News Conference News AHA 2018

Concerning Decline in Antibiotic Prophylaxis for Infective Endocarditis

November 19, 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Endoscopic Vein-Graft Harvest for CABG Associated With Similar MACE, Less Pain vs Open Procedure: REGROUP

News Conference News AHA 2018

Endoscopic Vein-Graft Harvest for CABG Associated With Similar MACE, Less Pain vs Open Procedure: REGROUP

Yael L. Maxwell

November 11, 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

November 10, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.